HG

Hamilton is firing on all cylinders at exactly the moment the market refuses to pay for it. FY2025 revenue of $2.91B (+24.7% YoY) and net income of $840M (+37.0%) extend a remarkable post-2022 ramp: revenue has more than doubled from $1.33B in FY2021 and net income has tripled off the FY2023 base, while diluted EPS jumped 51.2% to $5.55. The 28.9% net margin and 29.8% ROE are top-decile for a specialty (re)insurer, and management frames the strategy explicitly around 'sustainable underwriting profitability' rather than top-line chasing — the MD&A highlights Lloyd's Syndicate 4000 as 'among the most profitable and least volatile syndicates at Lloyd's over the last 10 years' and points to the hard US E&S market as the runway for Hamilton Select. At 5.9x trailing earnings, 0.7x sales, and roughly 0.77x book value ($2.82B equity vs. $2.17B market cap), the stock prices in a sharp earnings reversion that the filing's tone does not support.

The balance sheet backs the call. Equity grew 21.2% to $2.82B, retained earnings jumped 44.7% to $1.69B, long-term debt is a trivial $150M (basically flat YoY) and cash is $1.06B — leverage of 2.39x liabilities/equity is normal for a (re)insurer carrying loss reserves, not a sign of stress. Operating cash flow of $842M essentially matches reported net income, so earnings are converting to cash, not accounting accruals. Management is also returning capital — $113M of buybacks in FY2025 against a $2.17B cap is a ~5% repurchase yield, and with shares outstanding up only 2.8% the net dilution drag is modest.